# Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

> **NCT06816914** · PHASE2 · RECRUITING · sponsor: **Taichung Veterans General Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Resectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** NALIRIFOX

## Key facts

- **NCT ID:** NCT06816914
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-05
- **Primary completion:** 2027-02-05
- **Final completion:** 2028-02-05
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816914, "Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06816914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*